References
Gotto AM Jr, Moon JE (2012) Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 110(1 Suppl):3A–14A
Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, Manns B, Tonelli M, Shojania K (2012) Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet 379:2252–2261
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ (2012) Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380:565–571
Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S (2012) The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 60:875–881
Taskinen MR (2002) Controlling lipid levels in diabetes. Acta Diabetol 39(Suppl 2):S29–S34
Bugliani M, Liechti R, Cheon H, Suleiman M, Marselli L, Kirkpatrick C, Filipponi F, Boggi U, Xenarios I, Syed F, Ladiere L, Wollheim C, Lee MS, Marchetti P (2012) Microarray analysis of isolated human islet transcriptome in type 2 diabetes and the role of the ubiquitin-proteasome system in pancreatic beta cell dysfunction. Mol Cell Endocrinol. doi:10.1016/j.mce.2012.12.001
Masini M, Bugliani M, Lupi R, del Guerra S, Boggi U, Filipponi F, Marselli L, Masiello P, Marchetti P (2009) Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 52:1083–1086
Gallo R, Natale M, Vendrame F, Boggi U, Filipponi F, Marchetti P, Laghi Pasini F, Dotta F (2012) In vitro effects of mycophenolic acid on survival, function, and gene expression of pancreatic beta-cells. Acta Diabetol 49(Suppl 1):123–131
Masini M, Marselli L, Bugliani M, Martino L, Masiello P, Marchetti P, De Tata V (2012) Ultrastructural morphometric analysis of insulin secretory granules in human type 2 diabetes. Acta Diabetol 49(Suppl 1):247–252
Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T, Caputo S, Grzesk G, Kubica A, Swiatkiewicz I, Sukiennik A, Kelm M, De Servi S, Kubica J (2013) Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. doi:10.1016/j.amjcard.2012.12.037
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by Renato Lauro.
Rights and permissions
About this article
Cite this article
Bugliani, M., Syed, F., Masini, M. et al. Direct effects of rosuvastatin on pancreatic human beta cells. Acta Diabetol 50, 983–985 (2013). https://doi.org/10.1007/s00592-013-0465-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-013-0465-y